Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Voyager Therapeutics, Inc. VYGR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
68/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$14.40
+257.3%

Voyager Therapeutics, Inc. (VYGR) is a Biotechnology company in the Healthcare sector, currently trading at $4.03. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is VYGR = $14 (+257.3% upside).

Valuation: VYGR trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.38.

Financials: revenue is $40M, +131.2%/yr average growth. Net income is $120M (loss), growing at +50.6%/yr. Net profit margin is -296.5% (negative). Gross margin is 100% (+15.1 pp trend).

Balance sheet: total debt is $36M against $196M equity (Debt-to-Equity (D/E) ratio 0.19, conservative). Current ratio is 7.64 (strong liquidity). Debt-to-assets is 14.5%. Total assets: $252M.

Analyst outlook: 17 / 21 analysts rate VYGR as buy (81%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$14.40
▲ 257.32% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Voyager Therapeutics, Inc., the average price target is $14.40, with a high forecast of $18.00, and a low forecast of $8.00.
Highest Price Target
$18.00
Average Price Target
$14.40
Lowest Price Target
$8.00

VYGR SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VYGR

✓
VALUE Pass
100/100
VYGR trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25). Forward PEG 0.38 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $14, implying +247.4% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
VYGR: +131.2%/yr revenue is, +50.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
VYGR: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet VYGR: Debt-to-Equity (D/E) ratio 0.19 (conservative), Current ratio is 7.64 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
VYGR: Gross margin is 100% (+15.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 17 / 21 analysts rate VYGR as buy (81%). Analyst consensus target is $14 (+247.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VYGR: Net profit margin is -296.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.65-5.55
Volume868.57K
Avg Volume (30D)718.16K
Market Cap$240.19M
Beta (1Y)1.38
Share Statistics
EPS (TTM)-2.04
Shares Outstanding$58.69M
IPO Date2015-11-11
Employees172
CEOAlfred W. Sandrock Jr.
Financial Highlights & Ratios
Revenue (TTM)$40.37M
Gross Profit$40.37M
EBITDA$-127.78M
Net Income$-119.72M
Operating Income$-131.84M
Total Cash$196.45M
Total Debt$36.5M
Net Debt$-28.8M
Total Assets$252.28M
Price / Earnings (P/E)-2
Price / Sales (P/S)5.95
Analyst Forecast
1Y Price Target$18.00
Target High$18.00
Target Low$8.00
Upside+346.7%
Rating ConsensusBuy
Analysts Covering21
Buy 81% Hold 19% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92915B1061

Price Chart

Track all markets on TradingView
VYGR
Voyager Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.65 52WK RANGE 5.55

People Also View

ARWR
ARWR
Arrowhead Pharmaceuticals, Inc.
$70.95
+6.39%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 PRQR
PRQR
ProQR Therapeutics N.V.
$1.99
-0.50%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.36
+28.30%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message